Archives

Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors

B Clinical trial will evaluate safety, tolerability and antitumor activity of Repertoire’s novel off-the-shelf T cell receptor (TCR) bispecific therapy as monotherapy and in combination… Login to continue reading Login…

Read MoreRepertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors

ZeroEyes and High Tech High Collaboration Protects Students While Maintaining Open, Collaborative Learning Atmosphere

B Project-Based Charter School Network Demonstrates Commitment to Safety While Preserving Open, Relationship-Driven Culture PHILADELPHIA, April 23, 2026 /PRNewswire/ — ZeroEyes, creators of the leading AI-powered… Login to continue reading Login…

Read MoreZeroEyes and High Tech High Collaboration Protects Students While Maintaining Open, Collaborative Learning Atmosphere